Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Sanofi SA — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $24.84 (market cap $4.93B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 19.3× VanEck JP Morgan EM Local Currency Bond ETF's market cap, and Sanofi SA pays a 6.01% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck JP Morgan EM Local Currency Bond ETF for 38 Days and Sanofi SA for 94 Days on average.
| EMLC | SNY | |
|---|---|---|
Market Cap | $4.93B | $95.18B |
Volume | 2,843,860 | 2,995,646 |
Sector | Fixed Income | Health |
52-Week High | $26.59 | $52.34 |
52-Week Low | $24.53 | $39.51 |
Typical Hold Time | 38 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $24.84, showing minimal daily movement with a 0.28% gain. The ETF recently hit a 52-week low at $24.77, reflecting bearish technical signals from moving averages and ADX indicators. Recent news highlights challenges from dollar strength and Fed rate hikes affecting emerging market local currency bonds. The fund maintains dividend distributions with upcoming payments scheduled for October 2026.
Outlook remains cautious as technical indicators signal bearish momentum amid dollar strength headwinds. Investment opportunity exists for long-term investors seeking emerging market bond exposure with dividend income, though currency volatility and rising U.S. rates present significant risks to near-term performance.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
